Cargando…

Inhalable microparticles as drug delivery systems to the lungs in a dry powder formulations

Inhalation-administrated drugs remain an interesting possibility of addressing pulmonary diseases. Direct drug delivery to the lungs allows one to obtain high concentration in the site of action with limited systemic distribution, leading to a more effective therapy with reduced required doses and s...

Descripción completa

Detalles Bibliográficos
Autores principales: Knap, Karolina, Kwiecień, Konrad, Reczyńska-Kolman, Katarzyna, Pamuła, Elżbieta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845529/
https://www.ncbi.nlm.nih.gov/pubmed/36683752
http://dx.doi.org/10.1093/rb/rbac099
_version_ 1784870921003073536
author Knap, Karolina
Kwiecień, Konrad
Reczyńska-Kolman, Katarzyna
Pamuła, Elżbieta
author_facet Knap, Karolina
Kwiecień, Konrad
Reczyńska-Kolman, Katarzyna
Pamuła, Elżbieta
author_sort Knap, Karolina
collection PubMed
description Inhalation-administrated drugs remain an interesting possibility of addressing pulmonary diseases. Direct drug delivery to the lungs allows one to obtain high concentration in the site of action with limited systemic distribution, leading to a more effective therapy with reduced required doses and side effects. On the other hand, there are several difficulties in obtaining a formulation that would meet all the criteria related to physicochemical, aerodynamic and biological properties, which is the reason why only very few of the investigated systems can reach the clinical trial phase and proceed to everyday use as a result. Therefore, we focused on powders consisting of polysaccharides, lipids, proteins or natural and synthetic polymers in the form of microparticles that are delivered by inhalation to the lungs as drug carriers. We summarized the most common trends in research today to provide the best dry powders in the right fraction for inhalation that would be able to release the drug before being removed by natural mechanisms. This review article addresses the most common manufacturing methods with novel modifications, pros and cons of different materials, drug loading capacities with release profiles, and biological properties such as cytocompatibility, bactericidal or anticancer properties.
format Online
Article
Text
id pubmed-9845529
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-98455292023-01-19 Inhalable microparticles as drug delivery systems to the lungs in a dry powder formulations Knap, Karolina Kwiecień, Konrad Reczyńska-Kolman, Katarzyna Pamuła, Elżbieta Regen Biomater Review Inhalation-administrated drugs remain an interesting possibility of addressing pulmonary diseases. Direct drug delivery to the lungs allows one to obtain high concentration in the site of action with limited systemic distribution, leading to a more effective therapy with reduced required doses and side effects. On the other hand, there are several difficulties in obtaining a formulation that would meet all the criteria related to physicochemical, aerodynamic and biological properties, which is the reason why only very few of the investigated systems can reach the clinical trial phase and proceed to everyday use as a result. Therefore, we focused on powders consisting of polysaccharides, lipids, proteins or natural and synthetic polymers in the form of microparticles that are delivered by inhalation to the lungs as drug carriers. We summarized the most common trends in research today to provide the best dry powders in the right fraction for inhalation that would be able to release the drug before being removed by natural mechanisms. This review article addresses the most common manufacturing methods with novel modifications, pros and cons of different materials, drug loading capacities with release profiles, and biological properties such as cytocompatibility, bactericidal or anticancer properties. Oxford University Press 2022-12-08 /pmc/articles/PMC9845529/ /pubmed/36683752 http://dx.doi.org/10.1093/rb/rbac099 Text en © The Author(s) 2022. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Knap, Karolina
Kwiecień, Konrad
Reczyńska-Kolman, Katarzyna
Pamuła, Elżbieta
Inhalable microparticles as drug delivery systems to the lungs in a dry powder formulations
title Inhalable microparticles as drug delivery systems to the lungs in a dry powder formulations
title_full Inhalable microparticles as drug delivery systems to the lungs in a dry powder formulations
title_fullStr Inhalable microparticles as drug delivery systems to the lungs in a dry powder formulations
title_full_unstemmed Inhalable microparticles as drug delivery systems to the lungs in a dry powder formulations
title_short Inhalable microparticles as drug delivery systems to the lungs in a dry powder formulations
title_sort inhalable microparticles as drug delivery systems to the lungs in a dry powder formulations
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845529/
https://www.ncbi.nlm.nih.gov/pubmed/36683752
http://dx.doi.org/10.1093/rb/rbac099
work_keys_str_mv AT knapkarolina inhalablemicroparticlesasdrugdeliverysystemstothelungsinadrypowderformulations
AT kwiecienkonrad inhalablemicroparticlesasdrugdeliverysystemstothelungsinadrypowderformulations
AT reczynskakolmankatarzyna inhalablemicroparticlesasdrugdeliverysystemstothelungsinadrypowderformulations
AT pamułaelzbieta inhalablemicroparticlesasdrugdeliverysystemstothelungsinadrypowderformulations